Abbott Laboratories (ABT.xnys) is a multinational medical devices and health care company headquartered in Abbott Park, Illinois, America. Abbott sells medical devices, diagnostics, branded generic medicines and nutritional products, and its well-known products are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company operates in over 160 countries and employs 109,000 people. Due to the COVID-19 pandemic, Abbott delivered more than 400M tests at the beginning and 300M in the fourth quarter of 2020. Abbott has been an important key for detecting the complex virus and getting patients treatment but also brought faster testing with a low-cost rapid antigen test that helped schools and workplaces reopen earlier. The Abbott Laboratories stock (ABT.xnys) is listed on the New York Stock Exchange (NYSE), had a market capitalisation of $240.08B (USD) as of January 2022 and $34.61B in 2020 yearly revenue. Abbott, after the acquisition of WALK Vascular in September 2021, announced that the Food and Drug Administration (FDA) had approved new expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads.
Abbott Laboratories (ABT)
Stay informed with Abbott Laboratories (ABT) share price and trends to guide your investment strategy. Stay updated with FP Markets UK.